Induction of the NAD(P)H:quinone oxidoreductase 1 by ketoconazole and itraconazole: A mechanism of cancer chemoprotection

Cancer Letters

Volumn 258, Issue 1, 2007, Pages 135-143

  Korashy, Hesham M ^a   Brocks, Dion R ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antifungal drugs; Aryl hydrocarbon receptor; Carcinogenesis; NAD(P)H:quinone oxidoreductase 1; Transcription

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE INDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RNA SYNTHESIS; TRANSCRIPTION REGULATION; WILD TYPE;

ANIMALS; ANTIFUNGAL AGENTS; CARCINOMA, HEPATOCELLULAR; ENZYME ACTIVATION; ENZYME INDUCTION; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NAD; NAD(P)H DEHYDROGENASE (QUINONE); RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 35349030739     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.08.016     Document Type: Article

References (41)

1. Vasiliou V., Ross D., and Nebert D.W. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum. Genomics 2 (2006) 329-335
2. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 36 (2004) 639-654
3. Asher G., Lotem J., Sachs L., Kahana C., and Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. USA 99 (2002) 13125-13130
4. Smith M.T., Wang Y., Kane E., Rollinson S., Wiemels J.L., Roman E., Roddam P., Cartwright R., and Morgan G. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97 (2001) 1422-1426
5. Smith M.T., Wang Y., Skibola C.F., Slater D.J., Lo Nigro L., Nowell P.C., Lange B.J., and Felix C.A. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 100 (2002) 4590-4593
6. Iskander K., and Jaiswal A.K. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem. Biol. Interact. 153-154 (2005) 147-157
7. Korashy H.M., and El-Kadi A.O. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology 201 (2004) 153-172
8. Kann S., Huang M.Y., Estes C., Reichard J.F., Sartor M.A., Xia Y., and Puga A. Arsenite-induced aryl hydrocarbon receptor nuclear translocation results in additive induction of phase I genes and synergistic induction of phase II genes. Mol. Pharmacol. 68 (2005) 336-346
9. Jaiswal A.K. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 30 (1991) 10647-10653
10. Yoshinari K., Okino N., Sato T., Sugatani J., and Miwa M. Induction of detoxifying enzymes in rodent white adipose tissue by aryl hydrocarbon receptor agonists and antioxidants. Drug Metab. Dispos. 34 (2006) 1081-1089
11. Korashy H.M., and El-Kadi A.O. Transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase ya genes by mercury, lead, and copper. Drug Metab. Dispos. 34 (2006) 152-165
12. Mohora M. Role of Nad(P)h: quinone oxidoreductase in the regulation of intracellular redox state. Rom. J. Intern. Med. 38-39 (2000) 33-50
13. Denison M.S., Fisher J.M., and Whitlock Jr. J.P. Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex. J. Biol. Chem. 264 (1989) 16478-16482
14. Jaiswal A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 36 (2004) 1199-1207
15. Nioi P., and Hayes J.D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555 (2004) 149-171
16. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet 38 (2000) 111-180
17. Spanakis E.K., Aperis G., and Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43 (2006) 1060-1068
18. Caillot D., Bassaris H., McGeer A., Arthur C., Prentice H.G., Seifert W., and De Beule K. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis. 33 (2001) e83-e90
19. Sun G., Thai S.F., Tully D.B., Lambert G.R., Goetz A.K., Wolf D.C., Dix D.J., and Nesnow S. Propiconazole-induced cytochrome P450 gene expression and enzymatic activities in rat and mouse liver. Toxicol. Lett. 155 (2005) 277-287
20. Juberg D.R., Mudra D.R., Hazelton G.A., and Parkinson A. The effect of fenbuconazole on cell proliferation and enzyme induction in the liver of female CD1 mice. Toxicol. Appl. Pharmacol. 214 (2006) 178-187
21. Girois S.B., Chapuis F., Decullier E., and Revol B.G. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 119-130
22. Amin A., and Hamza A.A. Oxidative stress mediates drug-induced hepatotoxicity in rats: a possible role of DNA fragmentation. Toxicology 208 (2005) 367-375
23. Kanda N., and Watanabe S. Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid carcinoma A-431 cells. J. Invest. Dermatol. 119 (2002) 174-181
24. Ho Y.S., Wu C.H., Chou H.M., Wang Y.J., Tseng H., Chen C.H., Chen L.C., Lee C.H., and Lin S.Y. Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways. Food Chem. Toxicol. 43 (2005) 1483-1495
25. Zancan P., Rosas A.O., Marcondes M.C., Marinho-Carvalho M.M., and Sola-Penna M. Clotrimazole inhibits and modulates heterologous association of the key glycolytic enzyme 6-phosphofructo-1-kinase. Biochem. Pharmacol. 73 (2007) 1520-1527
26. Scholz M., Jennrich R., Strum S., Brosman S., Johnson H., and Lam R. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J. Urol. 173 (2005) 1947-1952
27. Nakabayashi M., Xie W., Regan M.M., Jackman D.M., Kantoff P.W., and Oh W.K. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107 (2006) 975-981
28. Wang Y.J., Jeng J.H., Chen R.J., Tseng H., Chen L.C., Liang Y.C., Lin C.H., Chen C.H., Chu J.S., Ho W.L., and Ho Y.S. Ketoconazole potentiates the antitumor effects of nocodazole: in vivo therapy for human tumor xenografts in nude mice. Mol. Carcinog. 34 (2002) 199-210
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
30. Dinkova-Kostova A.T., Fahey J.W., Wade K.L., Jenkins S.N., Shapiro T.A., Fuchs E.J., Kerns M.L., and Talalay P. Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 847-851
31. Cuendet M., Oteham C.P., Moon R.C., and Pezzuto J.M. Quinone reductase induction as a biomarker for cancer chemoprevention. J. Nat. Prod. 69 (2006) 460-463
32. Danson S., Ward T.H., Butler J., and Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat. Rev. 30 (2004) 437-449
33. Ho Y.S., Tsai P.W., Yu C.F., Liu H.L., Chen R.J., and Lin J.K. Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol. Appl. Pharmacol. 153 (1998) 39-47
34. Hegelund T., Ottosson K., Radinger M., Tomberg P., and Celander M.C. Effects of the antifungal imidazole ketoconazole on CYP1A and CYP3A in rainbow trout and killifish. Environ. Toxicol. Chem. 23 (2004) 1326-1334
35. Hasselberg L., Grosvik B.E., Goksoyr A., and Celander M.C. Interactions between xenoestrogens and ketoconazole on hepatic CYP1A and CYP3A, in juvenile Atlantic cod (Gadus morhua). Comp. Hepatol. 4 (2005) 2
36. Babin M., Casado S., Chana A., Herradon B., Segner H., Tarazona J.V., and Navas J.M. Cytochrome P4501A induction caused by the imidazole derivative Prochloraz in a rainbow trout cell line. Toxicol. In Vitro 19 (2005) 899-902
37. Kang Y.H., and Pezzuto J.M. Induction of quinone reductase as a primary screen for natural product anticarcinogens. Methods Enzymol. 382 (2004) 380-414
38. Dinkova-Kostova A.T., Fahey J.W., and Talalay P. Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). Methods Enzymol. 382 (2004) 423-448
39. Brass C., Galgiani J.N., Blaschke T.F., Defelice R., O'Reilly R.A., and Stevens D.A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob. Agents Chemother. 21 (1982) 151-158
40. Korashy H.M., Shayeganpour A., Brocks D.R., and El-Kadi A.O. Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole, in murine and human hepatoma cell lines: induction of cyp1a1 by antifungal drugs. Toxicol. Sci. 97 (2007) 32-43
41. Giudice A., and Montella M. Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention. Bioassays 28 (2006) 169-181